(24/7 Market News) We’re kicking off a full week, so we’re keeping an eye on short squeezes and the junior biotech/pharma space.
Boxed Inc (NASDAQ: BOXD) looks like it’s following through on last week’s move, at $2.54, up $0.22 (+9.48%), on 2.11 million premarket shares.
Redhill ADR (NASDAQ: RDHL) is another one that was in play last week and is trading at $0.863, $0.043 (+5.24%) higher, on 2.85 million shares.
We continue to cover Revlon (NASDAQ: REV), because it set the perfect bear trap and it looks like it’s consolidating and may make another run higher. It’s at $7.80, down 0.15 (-1.89%), on nearly 500 thousand shares, which is relatively low volume for the past couple of weeks.
Redbox Entertainment (NASDAQ: RDBX) was in the red for all of last week and may continue the trend, but it’s still above the 20 day moving average and well above the 50 and 200 day moving averages. Redbox is at $9.51, down $0.24 (-2.46%), on over 72 thousand shares traded, which could be a multi-month low.
Clovis Oncology Inc. (NASDAQ: CLVS) is a slower moving short squeeze, as compared to the Revlon and Redbox. It’s more than doubled since we started covering and it looks like it may trade between the 200 day moving average resistance and the 50 day moving average support. It’s at $1.77, up $0.07 (+4.12%) on over 500 thousand shares.
Evofem Biosciences (NASDAQ: EVFM) is at $0.645, $0.2731 (+73.43%) higher on 25.34 million shares.
Agile Therapeutics (NASDAQ: AGRX) is up to $1.62, 47 cents higher (+40.87%), on 9.17 million shares.
Acutus Medical (NASDAQ: AFIB) more than doubled in this morning’s premarket, at $1.15, up $0.61 (+113.60%) on over 12 million shares.
Epizyme (NASDAQ: EPZM) is at $1.54, up $0.586 (+61.43%) on 6.16 million shares.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.